Dr Robinson is currently a fixed-term Lecturer/Senior Lecturer in biochemistry and molecular cell biology, until July 2016. Teaching duties involve giving lectures and supervising laboratory practical sessions to both undergraduate and postgraduate biomedical students. Dr Robinson teaches in a number of biomedical fields, including pharmacology, biochemistry, forensic science, neuroscience, and toxicology. He also marks laboratory reports and oral presentations from the sessions he supervises, sets questions for examinations, and marks the submitted scripts.
Dr Robinson was a lecturer at Robert Gordon University, in Aberdeen, before coming to Nottingham Trent University. His primary role there was teaching second year pharmacy students the principles of pharmacokinetics, and also the pharmacology underlying various neurological diseases, such as anxiety, depression, and schizophrenia.
Before that, Dr Robinson was a Research Fellow at the University of Aberdeen for five years. His main focus of research was investigating the potential use of statins, the cholesterol-lowering drugs, in the treatment of asthma.
Dr Robinson's current research activities involve the potential role of statins in promoting the onset of type two diabetes, in collaboration with a Reader in Biomedical Molecular Biosciences at Nottingham Trent University, Dr Mark Turner.
Previously, Dr Robinson has worked with Dr Alan Hargreaves, a Reader in Biochemistry at Nottingham Trent University, in the field of organophosphate neurotoxicity. This resulted in one publication (see publications tab), and hopefully a further journal paper on this subject will be submitted soon.
Opportunities to carry out postgraduate research towards an MPhil/PhD exist in the School of Science and Technology and further information may be obtained from the NTU Graduate School.
Sponsors and collaborators
Dr Robinson is currently collaborating with Dr Mark Turner, Reader in Biomedical Molecular Biosciences at Nottingham Trent University.
- Diazoxon disrupts the expression and distribution of ßIII-tubulin and MAP 1B in differentiating N2a cells. Sachana M, Sidiropolou E, Flaskos J, Harris W, Robinson AJ, Woldehiwet Z and Hargreaves AJ, Basic and Clinical Pharmacology and Toxicology, 2014, 114, 490-496
- Fluvastain and lovastatin inhibit GM-CSF-stimulated human eosinophil adhesion to inter-cellular adhesion molecule-1 under flow conditions. Robinson AJ, Kashanin D, O'Dowd F, Fitzgerald K, Williams V and Walsh GM, Clinical and Experimental Allergy, 2009, 39, 1866-1874
- Recent developments in targeting eosinophil accumulation as a novel therapeutic approach for asthma. Walsh GM, Robinson AJ, Wu P, Open Allergy Journal, 2008, 7, 35-41
- Montelukast inhibition of resting and GM-CSF-stimulated eosinophil adhesion to VCAM-1 under flow conditions appears independent of CysLT1 antagonism. Robinson AJ, Kashanin D, O'Dowd F, Williams V and Walsh GM, Journal of Leukocyte Biology, 2008, 83, 1522-1529